The longest-running safety question in regenerative medicine just received its clearest answer yet. On July 21, 2026, a Keio University team published long-term results in Nature Medicine from the world’s first clinical study to transplant iPSC-derived neural stem cells into the injured human spinal cord. Through up to four years of follow-up, no participant developed a tumor, and no serious adverse event was attributed to the transplanted cells. For a technology whose defining risk has always been what reprogrammed cells might do years later, that result matters far beyond spinal cord injury.
This research update covers what the study found, the follow-on trial for chronic injuries announced at the ISSCR 2026 Annual Meeting, and what all of it does and does not mean for anyone researching stem cell therapy today. As always, we track new peer-reviewed publications like this one on our research page.
A World-First Trial Reports Four-Year Results
The study, led by Hideyuki Okano of the Keio University Regenerative Medicine Research Center and Masaya Nakamura of Keio’s Department of Orthopaedic Surgery, enrolled four adults with complete subacute spinal cord injuries, meaning recent injuries with no motor or sensory function below the damage. Each received a transplant of neural stem/progenitor cells derived from induced pluripotent stem cells (iPSCs), delivered directly to the injury site. The first procedure took place in late 2021, making this the first time reprogrammed stem cells were ever placed into an injured human spinal cord.
One-year results reported in 2025 showed no serious treatment-related adverse events and neurological improvement in two of the four participants, including one who regained the ability to stand independently and begin gait training. The new publication, released online in Nature Medicine on July 21, 2026 and summarized in the university’s official press release, integrates those first-year findings with extended follow-up of up to four years after transplantation.
| Question | What the study reported |
|---|---|
| Tumor formation | None observed in any participant through up to four years of follow-up |
| Serious adverse events | None attributable to the transplanted iPSC-derived cells |
| Motor function | Improvements observed; the proportion of participants with an improved AIS impairment grade at 52 weeks exceeded a historical control cohort |
| Study size | Four participants, open label, no randomized control group |
| Status | Investigational; not an approved therapy in any country |
Why “No Tumors” Is the Headline
Induced pluripotent stem cells are adult cells reprogrammed into a state where they can become nearly any cell type in the body. That flexibility is exactly what makes them powerful, and exactly what makes regulators cautious: if any cell in a transplanted dose remains incompletely differentiated, it could in principle keep dividing and form a tumor. This concern, more than any other, is why iPSC-based medicine has moved so deliberately since the technology earned the Nobel Prize in 2012.
Four years of tumor-free follow-up in the spinal cord, one of the least forgiving locations in the body, is therefore a milestone for the entire platform, not just for this trial. It strengthens the case behind the wave of iPSC-derived programs presented at ISSCR 2026 for Parkinson’s disease, retinal degeneration, and Huntington’s disease. Long-term safety evidence is the currency that lets all of these programs advance.
The Next Chapter: A Chronic Spinal Cord Injury Trial
The completed study treated subacute injuries, a narrow window of weeks after trauma. Most people living with spinal cord injury, roughly 300,000 in the United States by common estimates, are years past that window. Chronic injury is a biologically different problem: scar tissue has formed, and many surviving nerve fibers are intact but have lost the myelin insulation that lets signals travel.
At the ISSCR 2026 Annual Meeting, Okano presented the team’s answer, as covered by the ISSCR and the Regenerative Medicine Foundation: gliogenic neural stem/progenitor cells, or gNS/PCs. Rather than generating new neurons, these cells are tuned to produce the nervous system’s support cells, astrocytes and oligodendrocytes, with the goal of re-insulating demyelinated fibers that are still physically connected. Think of wiring that is intact but stripped of its coating; the strategy is to restore the insulation rather than lay new wire. The team reported a promising preclinical safety and efficacy package and is planning a physician-initiated clinical trial in chronic incomplete spinal cord injury, with patient recruitment targeted for 2027.
How to Read These Results Honestly
The safety conclusion is strong for what it is: a four-person, four-year dataset with no tumors and no serious cell-related harms. The efficacy signal deserves more caution. Subacute injuries can improve with rehabilitation alone, the study had no randomized control group, and a comparison against historical patients is suggestive rather than definitive. Two people improving out of four is a reason to run the next trial, not a demonstrated cure rate.
What This Means for Regenerative Medicine More Broadly
It helps to place this trial on the map of the wider field. iPSC-derived neural cells are a tissue-replacement strategy: build the missing cells and put them where they belong. Most regenerative products in clinical use or study today work differently. Mesenchymal stem cells and the exosomes they secrete act mainly as signaling agents that modulate inflammation and support the body’s own repair, the biology behind trials like the Phase 2b frailty study we covered earlier this year. Different tools, different questions, one field maturing along parallel tracks. Our benefits overview explains where each approach realistically fits.
The common thread is discipline. The Keio team spent more than a decade on preclinical safety work before its first patient, used clinical-grade cell manufacturing, and published its follow-up in a peer-reviewed journal. Patients evaluating the regenerative options that are accessible today should demand the same standard in miniature: documented sourcing, lot-level testing, and a certificate of analysis for the exact product being administered. That documentation standard is the foundation of our quality program and the reason practitioners choose OmniGenix.
Work With a Vetted OmniGenix Practitioner
Rigorous science deserves rigorous sourcing. OmniGenix supplies physician-grade, cGMP-manufactured regenerative products with full certificates of analysis, so your clinician can show you exactly what is in every dose.
Frequently Asked Questions
Can stem cell therapy cure spinal cord injury in 2026?
No. The Keio study shows long-term safety and early functional signals in four patients, which is encouraging but far from proof of a cure. No stem cell therapy is approved for spinal cord injury in the United States or Japan, and treatment remains available only through formal clinical research.
What are iPSC-derived neural stem cells?
They are neural stem/progenitor cells manufactured from induced pluripotent stem cells, which are adult cells reprogrammed to an embryonic-like state and then guided to become nervous system cells. They are designed to rebuild tissue, which is different from the mesenchymal stem cells and exosome products used in regenerative clinics, whose role is primarily signaling and immune modulation.
Was the transplanted cell therapy safe?
Through up to four years of follow-up, the researchers reported no tumor formation and no serious adverse events attributable to the transplanted cells in any of the four participants. That is the longest human safety record yet for iPSC-derived cells in the spinal cord, though a four-person study cannot rule out rare risks.
When will the chronic spinal cord injury trial begin?
The Keio team announced at ISSCR 2026 that it is preparing a physician-initiated trial of gliogenic neural stem/progenitor cells for chronic incomplete spinal cord injury, with patient recruitment targeted for 2027 in Japan. Enrollment criteria have not yet been published.
The Bottom Line
Four years without a tumor is the quiet headline of 2026 in regenerative medicine. It does not cure paralysis, and it does not put a product in any clinic. What it does is answer the question that has shadowed iPSC medicine since its invention, and it clears the path for a chronic injury trial built on a genuinely new strategy. The field earns trust the same way this team did: one documented, peer-reviewed step at a time. For help evaluating the regenerative options that exist today, our team and practitioner network are a good place to start.
Educational content only. Not medical advice. The iPSC-derived cell therapy described here is investigational and is not FDA-approved for spinal cord injury or any other use. Speak with a licensed clinician about whether regenerative medicine is appropriate for your case.